MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015

Emerging Infectious Diseases

Volumn 23, Issue 7, 2017, Pages 1079-1084

  Choe, Pyoeng Gyun ^a   Perera, R A P M ^b   Park, Wan Beom ^a   Song, Kyoung Ho ^a   Bang, Ji Hwan ^a   Kim, Eu Suk ^a   Kim, Hong Bin ^a   Ko, Long Wei Ronald ^b   Park, Sang Won ^a   Kim, Nam Joong ^a   Lau, Eric H Y ^b   Poon, Leo L M ^b   Peiris, Malik ^b   Oh, Myoung Don ^a  

^a Seoul National University   (South Korea)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASPIRATION PNEUMONIA; ASYMPTOMATIC INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; MICRONEUTRALIZATION ASSAY; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; REHABILITATION CARE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROEPIDEMIOLOGY; SOUTH KOREA; SPUTUM; SURVIVOR; VIRUS LOAD; VIRUS NEUTRALIZATION; BLOOD; CLASSIFICATION; CORONAVIRUS INFECTION; EPIDEMIC; GENETICS; HISTORY; IMMUNOLOGY; SERODIAGNOSIS; VIROLOGY;

CORONAVIRUS SPIKE GLYCOPROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; DISEASE OUTBREAKS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; HISTORY, 21ST CENTURY; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NEUTRALIZATION TESTS; REPUBLIC OF KOREA; SEROEPIDEMIOLOGIC STUDIES; SPIKE GLYCOPROTEIN, CORONAVIRUS;

EID: 85021110525     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2307.170310     Document Type: Article

References (18)

1. World Health Organization. WHO MERS-CoV global summary and risk assessment. 2016 Dec 5 [cited 2017 Jan 21]. http://www.who.int/emergencies/mers-cov/mers-summary-2016. pdf?ua=1
2. Reusken CB, Messadi L, Feyisa A, Ularamu H, Godeke GJ, Danmarwa A, et al. Geographic distribution of MERS coronavirus among dromedary camels, Africa. Emerg Infect Dis. 2014;20:1370–4. http://dx.doi.org/10.3201/eid2008.140590
3. Saqib M, Sieberg A, Hussain MH, Mansoor MK, Zohaib A, Lattwein E, et al. Serologic evidence for MERS-CoV infection in dromedary camels, Punjab, Pakistan, 2012–2015. Emerg Infect Dis. 2017;23:550–1. http://dx.doi.org/10.3201/eid2303.161285
4. Korea Centers for Disease Control and Prevention. Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015. Osong Public Health Res Perspect. 2015;6:269–78. http://dx.doi.org/10.1016/j.phrp.2015.08.006
5. Oh MD, Park WB, Choe PG, Choi SJ, Kim JI, Chae J, et al. Viral load kinetics of MERS coronavirus infection. N Engl J Med. 2016;375:1303–5. http://dx.doi.org/10.1056/NEJMc1511695
6. Kim ES, Choe PG, Park WB, Oh HS, Kim EJ, Nam EY, et al. Clinical progression and cytokine profiles of Middle East respiratory syndrome coronavirus infection. J Korean Med Sci. 2016;31:1717–25. http://dx.doi.org/10.3346/jkms.2016.31.11.1717
7. Park WB, Perera RA, Choe PG, Lau EH, Choi SJ, Chun JY, et al. Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea. Emerg Infect Dis. 2015;21:2186–9. http://dx.doi.org/10.3201/eid2112.151421
8. Corman VM, Albarrak AM, Omrani AS, Albarrak MM, Farah ME, Almasri M, et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis. 2016;62:477–83. https://dx.doi.org/10.1093/cid/civ951
9. Perera RA, Wang P, Gomaa MR, El-Shesheny R, Kandeil A, Bagato O, et al. Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill. 2013;18:20574. http://dx.doi.org/10.2807/1560-7917.ES2013.18.36.20574
10. Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis. 2016;22:1554–61. http://dx.doi.org/10.3201/eid2209.151164
11. Payne DC, Iblan I, Rha B, Alqasrawi S, Haddadin A, Al Nsour M, et al. Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerg Infect Dis. 2016; 22:1824–6. http://dx.doi.org/10.3201/eid2210.160706
12. Alshukairi AN, Khalid I, Ahmed WA, Dada AM, Bayumi DT, Malic LS, et al. Antibody response and disease severity in healthcare worker MERS survivors. Emerg Infect Dis. 2016;22:1113–5. http://dx.doi.org/10.3201/eid2206.160010
13. Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357:1162–3. http://dx.doi.org/10.1056/NEJMc070348
14. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105:435–46. http://dx.doi.org/10.1017/S0950268800048019
15. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al.; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90. http://dx.doi.org/10.1093/infdis/jiu396
16. Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015;4:709. http://dx.doi.org/10.1186/s40064-015-1490-9
17. Hemida MG, Perera RA, Al Jassim RA, Kayali G, Siu LY, Wang P, et al. Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity. Euro Surveill. 2014;19:20828. http://dx.doi.org/10.2807/1560-7917. ES2014.19.23.20828
18. Muth D, Corman VM, Meyer B, Assiri A, Al-Masri M, Farah M, et al. Infectious Middle East respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia. J Clin Microbiol. 2015;53:2951–5. http://dx.doi.org/10.1128/JCM.01368-15